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ABSTRACT 
 
INTRODUCTION  
Various prognostic models were devised to predict the future events in 
patients with cirrhosis, thereby help in listing the patients for transplantation. 
Model for end stage liver disease (MELD) is one such mathematical model which 
was found to be accurate in predicting mortality. MELD is usually preferred for 
organ allocation priorities whereas CTP score is preferred in daily practice.  
This study was carried out to know the efficacy of serum ferritin in predicting 
future events in patients with advanced liver disease. 
PRINCIPAL AIM OF THE STUDY was to study whether serum ferritin can 
independently predict the 15 day mortality in patients with advanced liver 
disease. 
 
 
MATERIALS AND METHODS  
This study was a prospective analytical evaluation, conducted at tertiary referral 
center, Department of Medical gastroenterology, Madras Medical College & Rajiv 
Gandhi Government General Hospital, Chennai. The evaluation period was from 
June 2013 to March 2014. Adult patients in age group 12 years and above with 
chronic liver disease were enrolled. Demographic data, medical history, co-
morbid history, drug history, anthropometric measurements and physical 
examination were extracted from prospective database. Routine blood 
investigations, liver biochemistry, metabolic work up, renal function tests, serum 
ferritin levels, relevant imaging of abdomen and upper G.I endoscopy were 
recorded. All the patients enrolled were followed up. Mortality was assessed at 
15th day of evaluation. Prognostic models along with serum ferritin were 
analysed. 
 
RESULTS 
A total of 75 consecutive patients were enrolled. 5 patients were excluded 
as 3 patients lost to follow up and 2 had HCC. Hence the total participants were 
70 patients. Among the 70 patients 65 were diagnosed to have decompensated 
cirrhosis and remaining 5 patients were in compensated phase of cirrhosis. None 
of the consecutive patients enrolled satisfied the criteria of Acute on Chronic Liver 
Failure. Male to female ratio was 8:1.  Majority of patients (49 patients) were in 
40 to 60 year age group. The clinical profile, laboratory investigations, prognostic 
models and outcome were looked upon.  All the patients involved in the study 
had jaundice at the time of presentation, 66 patients (94%) had ascites. 74 % of 
patients had encephalopathy. Majority of them were in lower grade. Mortality 
was found to be increased in higher grades of encephalopathy. 60 % of the 
patients evaluated had experienced upper G.I bleed.  Majority patients showed 
alcohol as the cause of liver disease, followed by HBV and NAFLD. Serum 
creatinine and serum sodium were found to be useful in predicting mortality. 
Bilirubin and transaminases were increased in all patients, but were not useful as 
prognostic marker.  CTP score, MELD and serum ferritin were found to be useful 
prognostic models in predicting outcome, but serum ferritin was superior to other 
two models. Addition of serum ferritin to MELD was found to increase the 
accuracy and precision. 
 
 
 
 
CONCLUSION 
 Serum ferritin levels were highly elevated in patients with early mortality. 
Serum ferritin as an independent prognostic appears to be convincing but large 
prospective multi-center studies should be carried out before being 
recommended in hepatology practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
INTRODUCTION 
 INTRODUCTION 
Cirrhosis may be detected in asymptomatic phase or symptomatic phase, the 
later presenting with complications of liver disease. Terminology used describe 
the above presentation is ‘compensated’ or ‘decompensated’1. 
Decompensation refers to condition when cirrhotics present with jaundice, 
ascites, hepatic encephalopathy or bleeding varices. They may also present with 
hepatorenal syndrome, hypernatremia and spontaneous bacterial peritonitis.  
Above terminologies are important for predicting prognosis and deciding 
treatment. 10 - Year survival in compensated cirrhotics is 50%, whereas among 
the decompensated, 18 month survival is 50%. Rate of decompensation is 10% 
among compensated liver disease patients2. Decompensated patients usually 
require liver transplantation. 
Various prognostic models were devised to predict the future events, 
thereby help in listing the patients for transplantation. Mathematical models are 
used in medicine for diagnosis, predicting prognosis and deciding treatment. 
Mathematical models can be diagnostic models, prognostic models or simulation 
models. Model for end stage liver disease (MELD) is one such mathematical 
model which was designed to know outcome in patients undergoing TIPS3. This 
was found to be accurate in predicting mortality in advanced liver disease4.  
Prognostic models should be statistically valid. Proportional hazards or Cox 
Regression analysis is the most appropriate statistical method for analysis. 
Valid model should have two important features ACCURACY and PRECISION6. 
Accuracy is the ability to predict the event which matches the observed event, 
whereas precision is the ability to reproduce the predicted event6. 
MELD is one such accurate and precise prognostic model though there are 
other valid and useful ones. Child-Turcott-Pugh score is the traditional model for 
assessing prognosis in advanced liver disease, though not developed using 
statistical analysis7. 
MELD is usually preferred for organ allocation priorities whereas CTP score 
is preferred in daily practice8. As liver transplantation is the only curative therapy 
in patients with advanced liver disease, these models help in prioritizing the 
patients for transplant. 
This study was carried out to know efficacy of serum ferritin in predicting future 
events in patients with advanced liver disease. 
 
 
  
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
Fibrosis is a healing response that occurs in injured tissues. The progression of 
fibrosis to cirrhosis leads to various sequelae.  
DEFINITION OF CIRRHOSIS 
Term cirrhosis was coined by Laennec in 1826, derived from the word ‘schirrous’. 
 Schirrous denotes orange or tawny surface of the liver seen at autopsy. 
Working party for the World Health Organization (WHO) in 1978 defines cirrhosis 
as a diffuse process characterized by fibrosis and the conversion of normal liver 
architecture into structurally abnormal nodules
9. 
Fibrosis alone or nodule formation without fibrosis is not cirrhosis. 
Causes  
Etiology  Treatment 
Viral hepatitis (B, C and D)                               Antivirals 
Alcohol                                                                Abstention 
NASH                                                                 Weight loss 
Iron overload (HFE) Venesection 
Haemochromatosis                                 Venesection 
Copper overload (Wilson ’s disease)  Copper chelator 
α 1 - antitrypsin defi ciency                            Transplant 
Type IV glycogenesis     Transplant 
Galactosaemia                                Withdraw milk and milk products 
Tyrosinaemia                                  Withdraw dietary tyrosine.  Transplant 
Primary biliary cirrhosis                                                           Transplant
Primary sclerosing cholangitis                                               Transplant
Hepatic venous outflow block 
Budd – Chiari syndrome                   
 
Relieve main veinblock.  Transplant 
Heart failure                                                                  Treat Cardiac cause 
Autoimmune hepatitis                                                
 
Immunosuppression 
Toxins and drugs, e.g. methotrexate, 
Amiodarone                                                                        
Identify and stop 
 
TABLE 1 
 
 
 
LIMITATIONS IN ETIOLOGICAL CLASSIFICATION 
The cause of cirrhosis is unknown in many cases, one cause may lead to 
many morphological patterns, and same form of cirrhosis may be caused many 
etiological factors. 
 
MORPHOLOGICAL CLASSIFICATION 
Size of liver 
1. Normotrophic cirrhosis 
2. Hypertrophic cirrhosis 
3. Atrophic cirrhosis  
Size of regeneration 
1. Fine-nodular (granular) cirrhosis  
2. Coarse-nodular (nodular) cirrhosis  
3. Coarse-bulbous (lobular) cirrhosis  
4. Mixed-nodular cirrhosis  
5. “Smooth” cirrhosis 
Structure of the fine tissue 
TABLE 2 
1. Multilobular (multiacinar) cirrhosis 
2. Monolobular (monoacinar) cirrhosis 
3. Mixed forms 
Progression of cirrhosis 
1. Active (progressive) form 
2. Inactive (stationary) form 
Completion of cirrhosis 
1. Complete form 
2. Incomplete form 
3. Incomplete septal cirrhosis 
CIRRHOSIS AND ITS CO-FACTORS  
Various co- factors like age, sex, duration may lead to progression of disease. 
 
 
FIG 1 
 
The above figure gives correlation between various etiologies and co-factors. 
 
 
 
CLINICAL CLASSIFICATION 
1. Latent form 
2. Manifest form 
 Active form – can manifest in 2 forms 1) stage of compensation, 2) 
stage of decompensation 
 Inactive form 
Decompensated liver disease – can have 2 forms  
Portal decompensation 
Metabolic decompensation 
Portal decompensation 
 Hypersplenism 
 Collateral varicosis 
 Portal hypertensive gastropathy 
 Hepatic encephalopathy 
 Oedema and ascites 
TABLE 3 
Metabolic decompensation 
Jaundice  
• Encephalopathy  
• Oedema, ascites  
• Disturbed coagulation  
• Impaired protein and carbohydrate metabolism 
• Disturbed biotransformation 
• Hormonal dysbalances 
• Altered pharmacokinetics 
• Bacterial and viral infections 
• States of deficiency 
 
TABLE 4 
NATURAL HISTORY 
Prognostic studies demonstrated that cirrhosis begins in asymptomatic 
state or “compensated”, which then progresses to a symptomatic or 
“decompensated” state, diagnosed by the presence of complications of cirrhosis 
such as ascites, variceal bleeding or encephalopathy. Compensated state may 
present in 2 phases. The first phase will not have any varices, mortality is below 
1%. In 2nd phase patient may develop varices with mortality about 3.4% per 
year12. 
 
Is cirrhosis reversible? 
Fibrosis reversal has been demonstrated in number of cases. Poynard et al. 
showed downgradation in metavir score in patients with HCV infection with stage 
F4 (cirrhosis), following combination treatment with pegylated interferon and 
ribavarin. But it could be due sampling error during needle biopsy10. This is been a 
subject of debate as there are confounding results from various other studies. 
Rat models and clinical models have demonstrated transformation from 
micronodular to macronodular cirrhosis with downgradation of cirrhosis. 
There has been improvement in hemodynamic status as well, but no single 
marker has found to demonstrate the improvement11. 
 
 
 
FIBROSIS PROGRESSION AND HISTOLOGICAL STATES 
Fibrosis develops slowly as the result of inflammation. Histologically 4 
stages have been describes based on Laennec cirrhosis classification13. The staging 
is done based on fibrous bands and nodule size. Thin fibrous bands and large 
nodules are seen in early stage14. Histological stages correlate clinically and to 
severity of portal hypertension. Non-invasive tests like fibroscan/ transient 
elastography are used to demonstrate fibrosis15. 
DEVELOPMENT OF VARICES AND ITS IMPACT ON PROGNOSIS 
Prevalence of varices in patients with cirrhosis is about 44%12. Varices 
develop at the rate of 5 -8 % per year in newly diagnosed cases of cirrhosis12. 
Hepatic vein pressure gradient (HVPG) measurement is useful in determining the 
development of varices16. Varices develop when HVPG is 10 mmHg or more. 
Average time for development of varices with or without bleed when HVPG is 
more than 10 mmHg is 4 years17. Modifying HVPG by therapies can change 
development and progression of varices. Size of varices is directly related to 
variceal bleed and mortality16, 17, 18. 
 
DECOMPENSATION 
Cirrhotic patients decompensate at the rate of 5 % per year19. Incidence is 
twice in patients with esophagogastric varices. Factors that predict 
decompensation are - the model for end stage liver disease (MELD)20, increased 
body mass index (BMI)22 albumin and hepatic vein pressure gradient ≥10 mmHg21.  
Ascites is the most frequent decompensating event, followed by bleeding, 
jaundice, and encephalopathy19. 
 
MORTALITY 
Mortality in asymptomatic cirrhosis is 1–3 % per year19, 20. It increases with 
development of varices.  Most common cause of death is a decompensating event 
or liver related event. 
COURSE OF DECOMPENSATED CIRRHOSIS 
Patients in compensated cirrhosis can decompensate with development of 
ascites, bleed, jaundice and encephalopathy19. 
ASCITES AND ITS COMPLICATION 
Patients with ascites usually have HVPG > 10 mm Hg21. Prevalence is 20 – 
60% in newly diagnosed cases23. Ascites develops at about 5% per year in 
compensated cases. Median survival after the appearance of ascites is 2 -4 
years23. Ascites can be complicated by refractory ascites, spontaneous bacterial 
peritonitis and Hepatorenal syndrome23, 24. 
 
REFRACTORY ASCITES 
Occurs in 5 -10% of cases with ascites24.  Defined as ascites, which cannot 
be mobilized even after therapeutic paracentesis, salt restriction and diuretics at 
maximum dose. 
Poor prognostic factors include low protein level in the ascitic fluid, increase in 
Child-Pugh score, previous history of SBP, and history of heavy alcohol 
consumption25. 
SPONTANEOUS BACTERIAL PERITONITIS  
One of the most common infection occurring in cirrhotics27. SBP Accounts 
for 25% of all infections occurring in cirrhosis27. SBP occurs at the rate of 65% in 
patients with cirrhotics. Mortality is increased when the patients develop SBP26, 27. 
HEPATORENAL SYNDROME 
HRS or functional renal failure occur when creatinine >1.5 mg/dL, not 
responding to plasma expansion in the absence of shock, no recent use of 
nephrotoxic drugs, and exclusion of parenchymal kidney disease28. 
Type I HRS has severe, rapidly progressive course where serum creatinine 
becomes >2.5 mg/dl in 2 weeks28.Type II HRS has slowly progressing course28. 
Incidence of HRS is about 15% in cirrhotics and median survival is only 6 months29. 
VARICEAL BLEED 
Variceal bleed occurs at rate of 5% per year32. Risk factors for bleed include 
variceal size, CTP score and red weal marks (newly formed vessels on the variceal 
wall) on Endoscopy34, 34. Bleeding stops spontaneously in 40–50 % of patients and 
bleeding can be controlled with therapy within 24 h from admission in nearly 85 
%. Six-week mortality after variceal bleeding is 10–15 %32, 33, 34, 35, 36. 
ENCEPHALOPATHY AND JAUNDICE  
Incidence of encephalopathy and jaundice is approximately 2–3 % per year. 
Encephalopathy can occur without ascites in the presence of spontaneous porta-
caval or spleno-renal shunt. Median survival after development of jaundice or 
encephalopathy is 1–2 years. 
HEPATOCELLULAR CARCINOMA 
Incidence of HCC in cirrhosis is 70 -90 %37, 38,38.  Hepatitis C virus (HCV) and 
hepatitis B virus (HBV) chronic infections constitute the most common risk factors 
for HCC38, 39. Elderly male (>55 years), increased α-fetoprotein (>20 ng/mL), and 
increased BMI are the factors affecting the prognosis38. Survival depends on the 
severity of the underlying disease and the degree of portal hypertension. 
Five stages of disease have been described - 
 
FIG 2 
 
FIG 3 
PROGNOSTIC INDICATORS 
Child Turcott Pugh Score is traditionally used clinical prognostic model to 
predict short term outcome40.  CTP SCORE, though not statistically validated, it is 
very useful score.  CTP score depends on jaundice, ascites, encephalopathy, serum 
albumin and coagulopathy40. 
MELD score, a mathematical model designed to determine prognosis in patients 
undergoing TIPS insertion. It depends on serum creatinine, prothrombin time 
(INR) and serum bilirubin. MELD is very useful in determining waiting list 
mortality41. The addition of serum sodium, MELD – Na improves the accuracy and 
precision in predicting outcome42. 
 
FIG 4 
 
UKELD was developed in U.K, uses INR, serum creatinine, serum bilirubin and 
serum sodium. It was found to have similar accuracy and precision as MELD – Na. 
Disease - specific scoring models were found helpful in assessing mortality. 
Maddrey’s discriminant function (MDF) determines hospital mortality and helps 
treatment decision in patients with alcoholic hepatitis. 
 It is calculated as follows: 
MDF = serum bilirubin (µ mol/L)/ 17 + Prolongation of prothrombin time in 
seconds compared to controls × 4.645,46. 
HVPG is also useful as independent predictor of death44. 
Serum ferritin, an acute phase reactant has shown favorable results in predicting 
mortality in cirrhotic patients awaiting liver transplant as an adjunct to MELD both 
in alcoholics and NAFLD patients47, 48, and 49. Hyperferritinemia was shown to 
associated with metabolic syndrome and plays a vital role in pathogenesis of liver 
injury60. Studies have shown that increased hepatic iron over-load is associated 
with increased risk of injury and progressive fibrosis61. Hepatic iron accumulation 
has been shown to be associated with HCC in NAFLD- related cirrhosis patients62. 
Animal models have also proven the mechanism of iron-dependent of cell death 
in pathogenesis of liver injury. This mechanism is called Ferroptosis63. Role of iron 
in liver injury is explained in the below figure. 
  
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
Aim and objectives of the study is  
1. To study whether serum ferritin can independently predict the 15 day 
mortality in patients with advanced liver disease 
2. To analyze demographic and clinical profile of patients with advanced liver 
disease. 
3. To study predictors of 15 day mortality in patients with advanced liver 
disease. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
 
MATERIALS AND METHODS 
This study was a prospective analytical evaluation, conducted at tertiary referral 
center, Department of Medical gastroenterology, Madras Medical College & Rajiv 
Gandhi Government General Hospital, Chennai. The evaluation period was from 
June 2013 to March 2014. Data was retrieved from prospectively enrolled medical 
records. Data was enrolled taking a formal informed consent. The study was 
approved by institute’s ethics committee. No formal statistical method was 
applied to determine sample size. 
 
INCLUSION CRITERIA 
Adult patients in age group 12 years and above with chronic liver disease, 
diagnosed according to AASLD guidelines were enrolled. Patients were diagnosed 
to have chronic liver disease if have nodular contracted liver on ultrasound, 
fibrosis ≥ 2 on histology, portal vein ≥13 mm, and oesophageal varices ≥2 on 
endoscopy.  
Adult patients in the age group 12 years and above with acute on chronic liver 
failure, diagnosed according to APASL guidelines were included.  
 
 
TABLE 5 APASL DEFINITION FOR ACLF 
 
 
 
EXCLUSION CRITERIA 
1. Age < 12 years and > 80 years. 
2. Pregnant woman. 
3. Patients with Hepatocellular Carcinoma. 
4. Any other malignancy. 
5. Patients with acute or sub-acute liver failure. 
6. Patients with HIV. 
 
METHODS 
Data was extracted by enrolling consecutive patients in prospective data 
base. Demographic data which included age & sex, medical history, co-morbid 
history and drugs and native medicine history was retrieved by interviewing the 
patients. A physical examination including anthropometric measurements was 
recorded. Alcohol intake was determined from the Alcohol Use Disorders 
Identification Test (AUDIT-C) questionnaires. 
 Medical history was recorded from the patients or attendants, which 
included presence or absence of jaundice, ascites, confusion, oliguria and upper 
G.I bleed. Thorough physical exam was done and details recorded which included 
information like icterus, ascites, pedal edema, spider nevi, gynecomastia, 
abdominal wall collaterals, hepatomegaly and splenomegaly. In conscious 
patients mini mental status assessment was done and thorough neurological 
examination was done. Presence of encephalopathy was recorded and classified 
base on modified West Haven criteria. Liver-related events were recorded, if any 
during the follow up.  
 
Blood investigations which included complete hemogram, hepatic 
biochemistries, metabolic labs,  renal fuction tests,  coagulation profile, liver 
enzymes, serum ferritin (Roche electrochemiluminance assay), and serological 
markers for HBV and HCV were recorded. Plasma GGT, AST, and ALT were 
measured by Boehringer methods. Serum ceruloplasmin, immunoglobulins, 
autoantibodies (Nuclear, mitochondrial and smooth muscle antibodies) were 
done and recorded if it was found to be positive.  
Presence of ascites, spontaneous bacterial peritonitis and HRS was 
recorded using International Ascites Club50 and AASLD practice guidelines51, 
respectively. 
Imaging studies like ultra sound abdomen with Doppler, Computer 
tomography or MRI scans were done. Presence of HCC if any was diagnosed using 
radiological criteria according to AASLD guidelines. Presence of varices was 
identified using upper G.I endoscopy and graded according to Paquet 
classification. 
 
TABLE 6.PAQUET CLASSIFICATION ESOPHAGEAL VARICES 
ASSESSMENT OF DISEASE SEVERITY 
 Maddrey’s discriminant function (MDF)45,46 was calculated for patients with 
alcoholic hepatitis and were classified in to groups, those with DF > 32 and with 
DF < 32. 
DF = serum bilirubin (µ mol/L)/ 17 prolongation of prothrombin time in seconds 
compared to controls × 4.6 
Child –Turcotte- Pugh score was calculated to assess severity of liver disease using 
table below. 
 
TABLE 7. CTP SCORE 
 
MELD52 was determined to prognosticate the patient using the below  - 
logarithmic equation.  (0.957 × log [creatinine mg/dl] + 0.378 × log [bilirubin 
mg/dl] + 1.120 × log [international normalized ratio] + 0.643). Patients were 
classified  into 3 groups based MELD values and analyzes. 
 
Patients were also classified into 3 groups based on serum Ferritin values. 
GROUP A – SERUM FERRITIN < 200 ng/ml 
GROUP B – SERUM FERRITIN 200 TO 400 ng/ml 
GROUP C – SERUM FERRITIN > 400 ng/ml 
Serum ferritin was analysed as trichotomous variable. 
All the patients enrolled were followed up. Mortality was assessed at 15th day of 
evaluation. 
 
 
 
 
 
 
 
 
 
STATISTICAL ANALYSIS  
Data was entered in Microsoft EXCEL sheet. Analysis was done using SPSS 
software version 20. 
Normally distributed variables will be expressed as mean ± standard 
deviation. Differences in categorical variables between groups will be assessed 
using Pearson’s chi-squared tests. Continuous variables were analysed by using T- 
test. Serum ferritin concentration will be analysed as a continuous and as a 
categorical variable. Kaplan-Meier survival curves will be used to show the 
survival in patients with high serum ferritin. Area under the receiver 
Operating characteristics (ROC) curves was used to analysis MELD and serum 
ferritin in predicting 15 day mortality. P - value < 0.05 was considered significant, 
if < 0.01, then highly significant 
 
 
 
 
 
 
 
  
 
 
 
 
RESULTS 
 
 
 
 
 
 
RESULTS 
A total of 75 consecutive patients were enrolled after taking informed 
consent in this prospective analytical study during the study period. 5 patients 
were excluded because 3 patients lost to follow up and 2 had been diagnosed to 
have HCC. 
Hence the total participants were 70 patients with advanced liver disease.  
Among the 70 patients 65 were diagnosed to have decompensated cirrhosis and 
remaining 5 patients were in compensated phase of cirrhosis. None of the 
consecutive patients enrolled satisfied the criteria of Acute on Chronic Liver 
Failure as defined by APASL. 
 
 
FIG 5 
DEMOGRAPHIC DATA 
During the evaluation of 70 patients with advanced liver disease, 62 of them were 
male and remaining female. Male to female ratio was 8:1. 
 
SEX NUMBER PERCENT 
MALE 62 88.6 
FEMALE 8 11.4 
TOTAL 70 100.0 
 
TABLE 8 
 
 
FIG 6 
 
The mean age of patients enrolled in this prospective study was 46 years. 
Majority of patients (49 patients) were in 40 to 60 year age group. 
 
FIG 7 
 
 
 
 
 
 
 
 
 
CLINICAL PROFILE 
 
 
FIG 8 
Among all the patients enrolled in the study all of them presented with jaundice. 
66 of the patients evaluated had ascites clinically, which amounts to 94.3%. All 
the clinical ascites had free fluid in imaging as well. 
 
Evaluation of clinical profile showed that 52 patients had encephalopathy, 42 
variceal bleed, 12 had hepatomegaly and 10 patients had splenomegaly. 
ASCITES 
 FIG 9 
ENCEPHALOPATHY  
Encephalopathy was diagnosed in patients enrolled with West Haven criteria. 
52 patients presented with some grade of hepatic encephalopathy. 18 were 
found to be normal according to the criteria. Of the 52 patients with H.E, majority 
had grade I encephalopathy. 
H.E NO OF CASES PERCENT 
 YES 52 74.3 
  NO 18 25.7 
  TOTAL 70 100.0 
 
TABLE 9 
 
 
GRADES OF H.E 
H.E GRADES NO OF CASES PERCENT 
NORMAL 18 25.7 
I 24 34.3 
II 1 1.4 
III 17 24.3 
IV 10 14.3 
TOTAL 70 100.0 
 
TABLE 10 
 
FIG 10 
VARICEAL BLEED  
During the study period, 42 patients enrolled experienced variceal bleed either at 
the presentation or during the course of evaluation. 
 
UGI BLEED 
VARICEAL 
BLEED FREQUENCY PERCENT 
 YES 42 60.0 
 NO 28 40.0 
 TOTAL 70 100.0 
 
TABLE 11 
 
FIG 11 
 
Among the patients analyzed, 7 were found to be diabetic during patient 
interview. All of them were on treatment. 
33 patients had the habit of smoking and majority of them were chronic smokers. 
 
DIABETICS NO OF CASES PERCENT 
 YES 7 10.0 
 NO 63 90.0 
 TOTAL 70 100.0 
 
TABLE 12 
SMOKERS NO OF PATIENTS PERCENT 
 YES 33 47.1 
  NO 37 52.9 
  TOTAL 70 100.0 
 
TABLE 13 
 
INCIDENCE OF ALCOHOLISM 
Among the patients evaluated, 51 patients were alcoholics. On interviewing the 
patients with AUDIT – C (Alcohol Use Disorders Identification Test) 
Questionnaire, all of them were having cirrhogenic dose, i.e   40 to 80 gm/day for 
10 years in male and 20 to 40 gm/day for 10 years in females. 
Alcohol as etiology for advanced liver disease was seen in 73% of cases.  
 
ALCOHOLICS NO OF PATIENTS PERCENT 
 YES 51 72.9 
NO 19 27.1 
TOTAL 70 100.0 
 
TABLE 14 
 
 
FIG 12 
OTHER AETIOLOGY  
Other etiological factors diagnosed in the study cases were Hepatitis B virus (HBV) 
alone in 9 cases, Hepatitis C virus (HCV) in 5 cases and Non-alcoholic Fatty Liver 
Disease (NAFLD) in 5 cases.  
CAUSES FREQUENCY PERCENT 
 HBV 9 20.0 
  HCV 5 10.0 
  NAFLD 5 7.1 
 
TABLE 15 
HBV was diagnosed in alcoholic patients in 5 cases, 2 alcoholic patients were 
found to have HCV. 
Majority patients showed alcohol as the cause of liver disease, followed by HBV 
and NAFLD. 
 
FIG 13. 
10 cases with advanced liver disease enrolled in the study had splenomegaly on 
examination 
LAB VALUES 
 N 
Minimu
m 
Maximu
m Mean 
Std. 
Deviation 
Age in years 70 21 67 45.91 9.603 
Wbc Cells/Cu Mm 70 4300 13000 6402.29 1740.700 
HB in gm% 70 2 14 8.33 2.146 
Platelets 
lacs/cumm 
70 .5 2.5 .882 .3841 
RBS 70 110 245 140.67 20.389 
Urea 70 20 56 28.01 7.552 
Creatinine 70 .5 4.3 1.323 .9907 
S.Sodium 70 111 145 136.50 8.262 
S.Potassium 70 2.4 5.7 3.726 .7064 
Bilurubin 70 2 26 11.41 6.755 
AST 70 43 984 362.46 213.847 
ALT 70 23 876 321.97 205.852 
ALP 70 67 364 120.44 47.818 
PROTEINS 70 5.00 7.00 5.7329 .43895 
ALBUMIN 70 2.1 6.1 2.731 .6693 
PT 70 13 35 22.70 5.783 
INR 70 .90 3.17 1.8081 .59394 
Serum ferrItin 
ng/ml 
70 9 2654 686.97 644.983 
 
TABLE 16 
Lab investigations showed varied findings. Most of them had anemia. Causes for 
anemia were variceal bleed, portal hypertensive gastropathy, alcoholic 
gastropathy and anemia due to chronic liver disease. 
 
 
White blood cell count was also found to be varied, however only 6 patients had 
evidence of spontaneous bacterial peritonitis. None of the patients had any other 
infection. Low counts could be due to hypersplenism or alcohol induced bone 
marrow suppression. 
Majority of the patients had low platelet count; mean platelet count among the 
study group was 88,000/cu.mm. Cirrhosis with portal hypertension, 
hypersplenism and bone marrow suppression would have been the cause for 
thrombocytopenia in these cases. 
Serum creatinine was elevated in 21 patients among 70 cases. Mean serum 
creatinine was 1.3. 
18 patients had low serum sodium; value below 135 mg/dl was taken as cut off 
for hyponatremia. Mean serum sodium value 136.5 mg/dl. 
10 patients in the study group had hypokalemia as well. 
All the patients enrolled in the study had elevated serum bilirubin and elevated 
transaminases. Mean serum bilirubin, AST & ALT value were 11.4, 362 & 321 
respectively. The reason for this elevation is due to loss of hepatocellular 
function, and all the chronic liver disease patients were in activity. 
Majority of the patient had low serum albumin and abnormal coagulation profile. 
The mean albumin value was 2.73 and mean INR was 1.8. The above values 
showed that the synthetic function of the liver was affected severely. Patients 
with anemia, Hb > 8 gm/dl received packed red cell transfusion. 10 patients 
received platelet transfusion when presented bleed and thrombocytopenia. 
Majority of the patients with altered renal function were managed conservatively. 
6 patients underwent hemodialysis.  
Patients with HRS and those with refractory ascites received albumin infusion. 
Fresh frozen plasma and injection vitamin K was given to patients with 
coagulopathy and bleed. 
VARICES IN ENDOSCOPY 
All the patients underwent endoscopy at some point during the study period. 63 
patients had esophageal varices. 6 had gastric varices. Patients presenting with 
variceal bleed underwent variceal band ligation or glue injection therapy for 
esophageal varices and gastric varices respectively. 
 
 
 
 
 
VARICES FREQUENCY PERCENT 
 YES 
63 90.0 
  NO 
7 10.0 
  TOTAL 
70 100.0 
 
TABLE 17 
 
FIG 14 
 
 
 
 
PORTAL HYPERTENSIVE GASTROPATHY 
 56 patients in our study group had portal hypertensive gastropathy. 
 
 
 
 
TABLE 18 
 
SPONTANEOUS BACTERIAL PERITONITIS 
6 out of 70 patients evaluated had spontaneous bacterial peritonitis 
diagnosed according to AASLD practice guidelines. All of them were treated with 
culture sensitive antibiotics. Initially patient with suspicion of SBP were treated 
with empirical antibiotics. 
 
SBP FREQUENCY PERCENT 
 YES 6 8.6 
  NO 64 91.4 
  TOTAL 70 100.0 
TABLE 19 
PHG NO OF CASES PERCENT 
 YES 56 80.0 
  NO 14 20.0 
  TOTAL 70 100.0 
 FIG 15 
PROGNOSTIC SCORES 
Disease specific prognostic score called Maddrey’s Discriminant Fraction was 
calculated for patients with alcoholic hepatitis. Patients with DF > 32 were given 
pentoxyfylline. Among 50 patients with alcoholic hepatitis 44 had DF > 32. 
MADDREY’S DISCRIMINANT FRACTION 
D.F NO OF CASES Percent 
 M.D.F < 32 
6 8.6 
  M.D.F > 32 
44 91.4 
 
TABLE 20 
 
CTP SCORE 
Child Turcott Pugh scores were calculated for all patients all of them were 
cirrhotics. Majority of the patients had CTP score more than 10 (59). 5 patients 
had CTP < 6 and 6 patients had score between 7 and 9. 
 
 
 
TABLE 21 
 
FIG 16 
 
 
 
 
CTP < 6 NO OF CASES PERCENT 
 CTP < 6 5 7.1 
 CTP 7 TO 9 6 8.6% 
 CTP > 10 59 84% 
MELD SCORE 
MELD prognostic score was calculated for all patients enrolled in study. Majority 
(77%) of the patients had score more than 20. 7 patients had MELD less than 9 &  
8 had between 10 and 19. 
MELD NO OF CASES PERCENT 
 < 9 7 10.0 
  10 - 19 8 11.4 
  > 20 54 77.1 
 
TABLE 22 
 
FIG 17 
 
 
 
SERUM FERRITIN LEVELS 
Serum ferritin levels were determined for all patients enrolled using Roche assay. 
ULN was defined as <200 ng/mL in women and <300 ng/mL in men; values were 
adopted from the Hemochromatosis and Iron Overload Screening Study. 
Average serum ferritin value was 686 ng /ml.  Maximum value was 2654 ng /ml. 
Serum ferritin was analysed as trichotomous variable dividing patients into 3 
groups as shown in table 25. Majority of the patients had serum ferritin levels 
more than 400 ng/ml as shown in table 23. Average serum ferritin levels in 
patients with early mortality was 1071 ng /ml and average level in patients who 
survived for more than 15 days was 363.47. 
SE. FERRITIN IN NG/ML NO OF CASES PERCENT 
 < 200 17 24.3 
  200 – 400 17 24.3 
  > 400 36 51.4 
 
TABLE 23 
 
 FIG 18 
 
 
FIG 18.1 
 
 
OUTCOME 
All 70 patients were followed up and the mortality was assessed on 15th day 
of evaluation during follow up. 31 patients had survival duration less than 15 
days, which accounts to 44.3 %. 
OUTCOME AT 15 DAYS FREQUENCY PERCENT 
 ALIVE 39 55.7 
  DEATH 31 44.3 
  TOTAL 70 100.0 
 
TABLE 24 
 
FIG 19 
 
 
SERUM FERRITIN LEVELS AND OUTCOME  
Serum ferritin was analysed a trichotomous variable. Analysis showed 17 
patients had serum Ferritin less than 200 ng / ml. Among the 17 patients, only 1 
patient had early mortality. There were 17 patients with serum Ferritin in the 
range, 200 to 400 ng / ml and 2 patients in this group had early mortality. 
Majority of the patients had serum ferritin value above 400 ng / ml. 29 patients 
out of 36 patients in this group had early mortality.  Serum ferritin was assessed 
as a categorical variable using Pearson’s Chi – square test. It was found to be 
highly significant P Value < 0.001, as shown in table 25 and 26. 
 
 
FIG 20 
 
   
Early Mortality 
Total < 15 > 15 
Serum 
Ferritin 
< 200 Count 1 16 17 
% within 
Serum 
Ferritin 
5.9% 94.1% 100.0% 
% within 
Early 
Mortality 
3.1% 42.1% 24.3% 
200-400 Count 2 15 17 
% within 
Serum 
Ferritin 
11.8% 88.2% 100.0% 
% within 
Early 
Mortality 
6.3% 39.5% 24.3% 
> 400 Count 29 7 36 
% within 
Serum 
Ferritin 
80.6% 19.4% 100.0% 
% within 
Early 
Mortality 
90.6% 18.4% 51.4% 
Total Count 32 38 70 
% within 
Serum 
Ferritin 
45.7% 54.3% 100.0% 
% within 
Early 
Mortality 
100.0% 100.0% 100.0% 
 
TABLE 25 
 
 
 Value df 
Asymp. 
Sig. (2-
sided) 
Pearson Chi-
Square 
36.374
(a) 
2 .000 
Likelihood 
Ratio 
41.137 2 .000 
Linear-by-
Linear 
Association 
30.971 1 .000 
N of Valid 
Cases 
70     
 
TABLE 26 
 
KAPLAN –MEIER SURVIVAL CURVES  
Kaplan – Meier survival curve analysis showed patients with high serum ferritin 
levels had increased early mortality. 
 
FIG 2 
CTP SCORE AND OUTCOME 
CTP score divided in to traditional 3 groups and assessed as a trichotomous 
variable using non-parametric Pearson’s Chi square test. Patients with CTP score 
less than 6 and group of patients with CTP score between 7 and 9 had no early 
mortality. In other words they survived for more than 15 days. Patient group with 
CTP score > 10 had 54.2 % early mortality, 45.8 % survived more than 15 days. 
This was also highly significant, P Value < 0.005, as shown in table 27 and 28. 
   
EARLY MORTALITY 
TOTAL < 15 > 15 
CTP < 6 COUNT 0 5 5 
% WITHIN CTP .0% 100.0% 100.0% 
% WITHIN EARLY MORTALITY .0% 13.2% 7.1% 
7-9 COUNT 0 6 6 
% WITHIN CTP .0% 100.0% 100.0% 
% WITHIN EARLY MORTALITY .0% 15.8% 8.6% 
> 10 COUNT 32 27 59 
% WITHIN CTP 54.2% 45.8% 100.0% 
% WITHIN EARLY MORTALITY 100.0% 71.1% 84.3% 
TOTAL COUNT 32 38 70 
% WITHIN CTP 45.7% 54.3% 100.0% 
% WITHIN EARLY MORTALITY 100.0% 100.0% 100.0% 
TABLE 27 
  
FIG 22 
 
 
 Value df 
Asymp. 
Sig. (2-
sided) 
Pearson Chi-
Square 
10.990(
a) 
2 .004 
Likelihood 
Ratio 
15.159 2 .001 
Linear-by-
Linear 
Association 
9.511 1 .002 
N of Valid 
Cases 
70     
 
TABLE 28 
MELD AND OUTCOME  
Calculated MELD analysed by dividing the patients in to 3 group, as trichotomous 
variable. Again Pearson’s Chi square test was used analyse the categorical 
variable. It was found that out of 55 patients in high MELD group, 32 had early 
mortality, which was 58.2 %. 8 patients had MELD between 10 and 19. No early 
mortality seen in this group. In group of patient with MELD < 9, no early mortality 
seen, this correlation was highly significant, P Value < 0.001 as shown in table 29 
and 30. 
 
   
EARLY MORTALITY 
TOTAL < 15 > 15 
MELD < 9 COUNT 0 7 7 
% WITHIN MELD .0% 100.0% 100.0% 
% WITHIN EARLY MORTALITY .0% 18.4% 10.0% 
10-19 COUNT 0 8 8 
% WITHIN MELD .0% 100.0% 100.0% 
% WITHIN EARLY MORTALITY .0% 21.1% 11.4% 
> 20 COUNT 32 23 55 
% WITHIN MELD 58.2% 41.8% 100.0% 
% WITHIN EARLY MORTALITY 100.0% 60.5% 78.6% 
TOTAL COUNT 32 38 70 
% WITHIN MELD 45.7% 54.3% 100.0% 
% WITHIN EARLY MORTALITY 100.0% 100.0% 100.0% 
 
TABLE 29 
 FIG 23 
 
 Value df 
Asymp. 
Sig. (2-
sided) 
Pearson Chi-
Square 
16.077(
a) 
2 .000 
Likelihood 
Ratio 
21.759 2 .000 
Linear-by-
Linear 
Association 
13.813 1 .000 
N of Valid 
Cases 
70   
 
TABLE 30 
 
 
Early 
Mortality N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Sodium < 15 
32 132.38 10.067 1.780 
> 15 
38 139.97 3.908 .634 
TABLE 31 
Our study group patients also had subnormal serum sodium levels. Mean serum 
sodium was 136.5 mg/dl. In patients with early mortality mean serum sodium was 
132.38 mg/dl. Serum sodium levels were analysed as independent prognostic 
marker using T-test. It was found to be highly significant, P Value < 0.001. 
 
 
ROC CURVE ANALYSIS 
ROC Curve analysis of 15-day mortality was done to assess if serum ferritin alone 
or serum ferritin in addition to MELD improved the prediction of mortality when 
compared to MELD alone. 
 
 
 
 
ROC CURVE ANALYSIS FOR SERUM FERRITIN 
 
FIG 24 
Area 
Std. 
Error(a) 
Asymptotic 
Sig.(b) 
Asymptotic 95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
.866 .046 .000 .775 .956 
 
AUROC for serum ferritin is .866 
 
 
ROC CURVE ANALYSIS MELD 
FIG 25 
 
Area 
Std. 
Error(a) 
Asymptoti
c Sig.(b) 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
.689 .063 .007 .566 .811 
 
AUROC for MELD IS .689. This was found to be statistically significant. 
 
 
 
ROC CURVE ANALYSIS FOR SERUM FERRITIN + MELD 
 
FIG 26 
 
Test Result 
Variable(s) 
Area 
Std. 
Error(a) 
Asymptot
ic Sig.(b) 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Meld Score .689 .063 .007 .566 .811 
Serum ferrItin 
ng/ml 
.866 .046 .000 .775 .956 
 
ROC CURVE analysis for serum ferritin in addition to MELD has increased the Area 
Under Curve by 20 % from .689 to .866. this was found statistically significant . 
  
 
 
DISCUSSION 
 
 
 
 
 
DISCUSSION 
Various studies were conducted to evaluate the usefulness of serum Ferritin as 
prognosticating factor in patients with advanced liver. Results were found to be 
conflicting.  Skikne et al., 1990 showed direct correlation between body iron 
stores and serum ferritin. Serum ferritin also increases because of liver injury, 
inflammation, infection and malignancy. Patients with alcoholic liver disease and 
NAFLD have been shown to have increased body iron stores and increase release 
of ferritin following liver injury and decreased clearance from circulation, thereby 
increasing the baseline serum ferritin values. 30 % of patients with cirrhosis found 
to have increased ferritin independent of HFE mutations53 & 54.  Moreover ferritin is 
found to be a pro-inflammatory cytokine involved in inflammatory process 
causing liver injury55. Possibly direct relation between serum ferritin and 
inflammatory activity in liver is the cause of early mortality. 
This is a prospective analytical study conducted at tertiary referral center in 
southern part of India, to analyse the usefulness of serum ferritin, a non-invasive 
prognostic marker of liver disease. 70 consecutive patients with cirrhosis were in 
this study. The clinical profile, laboratory investigations, prognostic models and 
outcome were looked upon.  
 All the patients involved in the study had jaundice at the time of presentation, 66 
patients (94%) had ascites. 74 % of patients had encephalopathy. Majority of 
them were in lower grade. Mortality was found to be increased in higher grades 
of encephalopathy. None of the patients had fever any time during the study 
period. 
60 % of the patients evaluated had experienced upper G.I bleed at some point 
during the duration of study. 10 % of the patients were diabetic and were on 
treatment. 
On interviewing the patients, it was found that 73 % of the patients were 
alcoholic and 47 % were smokers. All of them were having cirrhogenic dose of 
alcohol, i.e   40 to 80 gm/day for 10 years in male and 20 to 40 gm/day for 10 
years in females. 
Alcohol as etiology for advanced liver disease was seen in 73% of cases, the most 
common cause of cirrhosis in the study group.  
Other etiological factors diagnosed in the study cases were Hepatitis B virus (HBV) 
alone in 9 cases, Hepatitis C virus (HCV) in 5 cases and Non-alcoholic Fatty Liver 
Disease (NAFLD) in 5 cases.  
HBV was diagnosed in alcoholic patients in 5 cases, 2 alcoholic patients were 
found to have HCV. Majority patients showed alcohol as the cause of liver 
disease, followed by HBV and NAFLD.  
Similar study done by Walker et al showed viruses as the most common cause of 
cirrhosis49.  Few studies have shown alcohol as the most common etiology 
followed by viral hepatitis. This finding could be due referral bias, as our hospital 
gives free treatment for poor patients.  
Analysis of laboratory values showed very low average haemoglobin (8.3 gm/dl) 
and platelet count (80,000/cu.mm). 
 Anaemia could have been due to variceal bleed, portal hypertensive gastropathy, 
alcoholic gastropathy and anemia due to chronic liver disease. Reason for low 
platelet count could be due to portal hypertension and hypersplenism.   
Mean creatinine in this group of patients was 1.3. Patients with early mortality  
had high serum creatinine. Using multiple linear regression analysis in SPSS 
software, serum creatinine was shown to be independent prognostic factor in 
above patients.  
All the patients had high serum bilirubin; mean bilirubin value was 11.4 mg/dl. 
Transaminases were also found be high, mean ALT value was 362.46 IU/L and 
mean AST was 321.97 IU/L.  
Walker et al49 showed similar findings in study. 
These finding support the on-going necroinflammatory activity in the study 
patients. Above finding is also supported by increased mean serum ferritin value. 
As already discussed ferritin is a pro-inflammatory cytokine, which is released 
from liver when there is necro - inflammation55. 
Mean serum bilirubin value and transaminase levels in patients with early 
mortality were high when compared to survivors.  
Our study group patients also had subnormal serum sodium levels. Mean serum 
sodium was 136.5 mg/dl. In patients with early mortality, mean serum sodium 
was 132.38 mg/dl. Serum sodium levels were analysed as independent prognostic 
marker using paired T - test. It was found to be highly significant. 
Kim et al42 showed hyponatremia as an independent marker of mortality and 
addition of sodium to MELD increased the accuracy in predicting early mortality. 
CTP score was analysed in patients with early mortality and survivors, it was 
found that, patients with high CTP score had significantly increased early 
mortality. 
Similarly MELD score was analysed in patients with early mortality, patients with 
high MELD score also had increased early mortality, which was highly significant 
statistically. These findings were in accordance to the finding shown by two 
landmark studies. 
Infante – Rivard et al40  analysed the prognostic markers in cirrhotic patients, 
showed patients with high CTP scores had poor prognosis and required early 
transplant. 
Olthoff et al41 showed patient with cirrhosis should be allotted organs based on 
MELD score in adults and PELD score in children, as patients with high score had 
increased early mortality. 
Serum ferritin levels measured in the study showed elevated mean value 686 
ng/ml. Mean value of serum ferritin in patients with early mortality was high, 
1071.04 ng/ml.  
Serum ferritin was analysed as a trichotomous variable diving into 3 groups and 
patient group with high serum ferritin had high early mortality, this was 
statistically highly significant.  
ROC curve analysis for 15 day mortality showed that serum ferritin is better than 
MELD in predicting mortality. Addition of serum ferritin to MELD further improves 
the predictability.  This was also highly significant statistically. 
In similar study by Walker et al49 in patients awaiting liver transplant, showed 
high mortality in patients with high serum ferritin. 
Walker et al49 also demonstrated that, ROC curve analysis of serum ferritin and 
MELD in predicting mortality was better than MELD alone, but it was not 
statistically significant. 
Manousou et al55 showed high serum Ferritin predicts fibrosis and inflammation 
in NAFLD patients. 
Similar finding was shown by Knowdley et al58. 
But the conflicting evidence was given by Chandok et al59, they found that the 
base line ferritin levels were high in NAFLD patients but did not predict the 
severity of liver disease. 
Vagu C et al57 also showed that serum iron markers were useful as predictors of 
severe liver injury in chronic Hepatitis C patients. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
Serum ferritin levels are highly elevated in patients in with advanced liver disease. 
It is demonstrated to be the marker of increased hepatic iron load and 
necroinflammatory activity. Levels are elevated due increased release from liver 
cell and decreased removal from circulation. 
This prospective analytical study done in tertiary referral center in south 
India has shown that the most common cause for cirrhosis is alcohol. All patients 
included in the study had high bilirubin and elevated transaminases. They were 
found to be not useful in predicting mortality. Serum creatinine and serum 
sodium levels were found to be useful in predicting the outcome of patients with 
liver disease.  
Serum ferritin levels were highly elevated in patients with early mortality. It 
was found to be highly accurate in predicting early mortality in cirrhotic patients. 
MELD score was also found to useful in predicting the outcome of patients with 
advanced liver disease, but serum ferritin was found to be superior in predicting 
mortality.  
Serum ferritin as an independent prognostic appears to be convincing but 
large prospective multi-center studies should be carried out before being 
recommended in hepatology practice. 
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ANNEXURE 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
ACLF Acute on Chronic Liver Failure  
 
APASL 
 
AASLD 
Asia Pacific Association of Study of Liver 
 
American Association Study Of Liver Disease 
 
CTP Child Turcott Pugh 
 
EASL European Association of Study of Liver 
 
INR International Normalised Ratio 
 
IL Interleukin 
 
MDF Maddrey’s Discriminant Function 
 
MELD 
 
HVPG 
Model for End stage Liver Disease 
 
Hepatic vein pressure gradient 
 
BMI                Body Mass Index 
SBP                Spontaneous Bacterial Peritonitis 
HRS                Hepatorenal Syndrome 
H.E                 Hepatic Encephalopathy 
HCC               Hepatocellular Carcinoma 
HBV               Hepatitis B Virus 
HCV               Hepatitis C Virus 
HIV                Human Immunodeficiency Virus 
AUDIT-CAlcohol Use Disorders Identification Test 
ALT                  Alanine Amino Transferase 
AST                 Aspartate Amino Tranferase 
GGT                Gamma GlutamylTransferase 
ROC                 Receiver Operating Curve 
PHG                 Portal Hypertensive Gastropathy 
UGI                  Upper Gastrointestinal Tract 
NAFLD            Non-Alcoholic Liver Disease 
PT                    Prothrombin Time 
INR                  InternationNormalised Ratio           
Proforma 
Name  IP no  D.O.A  
Age  + Unit  D.O.Discharge 
D.O.Death 
 
Sex  Ward  Duration of stay  
Address Diagnosis 
Phone No. 
History 
Jaundice   Altered sensorium   
Abdominal 
Distension 
  Hematemesis   
Pedal edema   Malena   
Oliguria   Weight loss   
Puffiness of face   Spontaneous bleeding   
Fever   Muscle cramps   
Anorexia   Cough   
fatigue   Breathlessness   
Constipation   Diet    
Diarrhea      
Native medication      
Past h/o jaundice   Tattooing   
Diabetes   Blood transfusion   
Smoking   Drug abuse   
Alcohol 
Duration 
Gm/day 
 
Tuberculosis   
Examination 
HE grade  Clubbing  PR  
Nutrition  Cyanosis  RR  
Height  Parotid swelling  Temp  
Weight  Gynaecomastia  BP Systolic  
BMI  Palmar 
erythema 
 Diastolic  
Anaemia  Scrotal swelling  Pulse pressure  
Icterus  Skin changes  Neck veins  
Pedal edema  Abd veins  CVS  
Ascites  Back veins  RS  
Umblical hernia  Caput medusae    
Splenomegaly  Hepatomegaly    
Investigation 
USG Abdomen 
Liver Size 
Echoes 
Ascites 
Spleen 
Endoscopy 
PV Doppler CXR 
CRP  
Ascitic fluid culture 
Colour 
SAAG 
Cell count 
SERUM FERRITIN  
Blood culture  
CTP   Urine culture  
MELD  HBsAg  Steroids  
APACHE  HCV  pentoxyfylline  
SOFA  Anti HEV    
HRS  HIV    
Date      
  
Remarks  
TC      
Hb      
Platlet      
RBS      
Urea      
Creatinine      
Sodium      
Potassium      
Bilurubin TOT      
Direct      
Indirect      
SGOT      
SGPT      
ALP      
Protein      
Albumin      
Globulin      
PT      
INR      
ABG      
Lactate      
 
Information sheet 
 
We are conducting a study on “Serum Ferritin – An Independent Prognostic Marker in 
predicting early mortality in Advanced Liver Disease” at The Department of Medical 
Gastroenterology, Rajiv Gandhi Govt General Hospital, Chennai. The purpose of the study is to 
know whether serum ferritin predicts early mortality in patients in Decompensated Chronic 
Liver Disease and Acute on Chronic Liver Failure. 
 
The privacy of the patients in this research will be maintained throughout the study.In 
the event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared. 
 
Taking part in this study is voluntary. You are free to decide whether to participate in 
this study or to withdraw at any time. Your decision will not result in any loss of benefits to 
which you are otherwise entitled. 
 
The results of the study may be intimated to you at the end of the study period or 
during the study if anything is found abnormal. This may aid in the management or treatment. 
 
 
Signature of Investigator                                                                Signature of participant 
 
Date:  
INFORMED CONSENT FORM 
 
Title of the Study:  
Serum Ferritin – An Independent Prognostic Marker in predicting Early mortality in Advanced 
Liver Disease 
Name of the Participant: 
_______________________________________  
 
Name of the Investigator: Dr. ShujaathAsif.M 
 
Name of the Institution :   Madras Medical College. 
 
Documentation of the informed consent 
 
I _________________________  have read the information of this form (or it had been read to 
me). I was free to ask any questions and they have been answered. I  hereby give my consent to 
be included as a participant in 
Serum Ferritin – An Independent Prognostic Marker in predicting Early mortality in Advanced 
Liver Disease 
 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator.  
 Name and signature / thump impression of the participant 
Name _____________________ Signature _____________ Date____ 
 
Name and signature of impartial witness (required for illiterate patients): 
 
Name _____________________ Signature _____________ Date____ 
 
Address and contact number of the impartial witness: 
 
Name and signature of the investigator or his representative obtaining consent: 
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1 BALAN 1777/13 56 M Y Y y 3 N Y N Y Y N
2 SANTHANAM2103/13 48 M Y Y Y 3 N Y N Y Y N
3 KUMUDHA 1724/11 27 F Y Y Y 3 N Y N N N HBV
4 VELU 7415/12 48 M Y Y Y 3 N Y N Y Y N
5 RAGHUPATHY734/12 56 M Y Y Y 1 N N N N Y N
6 PALANI 3930/13 43 M Y Y Y 3 N Y N Y Y N
7 SARAVANAN2267/13 36 M Y Y Y 1 N Y N Y Y N
8 GUNASEKARAN4519/13 45 M Y Y Y 3 N Y N Y Y N
9 KUMAR 4718/13 40 M Y Y Y 1 N N N N Y HBV
10 GOVIND 489/13 34 M Y Y Y 1 N N N N Y N
11 RAJAGOPAL4571/13 38 M Y Y Y 1 N N N N Y N
12 RAJU 3890/13 43 M Y Y Y 1 N Y Y N N NAFLD
13 MUNUSAMY2294/13 50 M Y Y Y 1 N N N Y Y N
14 GOVINDAN5047/13 51 M Y Y Y 1 N N N Y Y N
15 RAMESH 4098/13 46 M Y Y Y 1 N N N Y Y N
16 VADIVEL 4735/12 32 M Y N N N N N N N Y N
17 GUNALAN 4614/13 45 M Y Y Y 1 N N N Y Y HBV
18 THIRUPATHI3986/12 43 M Y Y Y 1 N N N N Y N
19 RADHAKRISHNAN4654/13 44 M Y Y N N N N N Y Y N
20 LOGANATHAN4492/13 34 M Y Y Y 1 N N N Y Y N
21 RATHNAM 5364/13 34 M Y Y Y 1 N N N Y Y N
22 RATHNA KUMAR5677/12 45 M Y Y Y 1 N Y N Y Y N
23 MANOHARAN6798/13 47 M Y Y Y 2 N Y N Y Y N
24 ARUMUGAM5678/13 56 M Y Y Y 3 N Y N Y Y N
25 SANTHANAM2103/132103/13 56 M Y Y Y 1 N Y N Y Y HCV
26 ARUMUGAM6837/13 45 M Y Y Y 1 N Y Y N N HBV
27 MANI 4567/12 45 M Y N N N N N N N N HCV
28 RAJ 6137/12 48 M Y Y Y 3 N Y N N N HBV
29 SHEIKH MOHD4673/13 54 M Y Y Y 3 N Y N Y Y N
30 ALLAH BAKSH5672/11 56 M Y Y Y 4 N Y Y Y N HBV
31 KARTHIK 3456/12 45 M Y Y Y 3 N Y N Y Y N
32 RAJA 5437/12 65 M Y Y Y 1 N Y N N Y HBV
33 JAGADISH 4563/13 44 M Y Y Y 1 N N N N Y N
34 SATHEESH 4785/12 39 M Y Y Y 4 N Y N N Y N
35 DEVENDRAN5133/13 54 M Y Y Y 3 N Y N Y Y N
36 RANI 6756/12 45 F Y Y Y 3 N N Y N N NAFLD
37 LAKSHMI 2564/11 67 F Y Y Y 4 N Y N N N HBV
38 MURUGAN 4785/11 54 M Y Y Y 4 N N N Y Y N
39 KONDAIYAN4414/13 50 M Y Y Y 4 N Y N N Y HBV
40 JEYARAM 1706/11 37 M Y Y Y 1 N Y N N N HCV
41 VENKATESAN6619/10 30 M Y Y Y 1 N N N N Y N
42 BALAMURTHY3324/13 22 M Y Y Y 1 N Y N Y Y N
43 RAVI 6044/13 55 M Y Y Y 4 N Y N Y Y N
44 SARAVANAN6215/132 39 M Y Y Y 4 Y N N N Y HCV
45 PARASURAM6235/13 34 M Y Y Y 1 N N N N N HBV
46 MALA 1394/09 21 F Y Y N N N N N N N HCV
47 SRINIVASAN6315/12 54 M Y Y N N N Y N Y Y N
48 GOWTHAMAN5400/13 56 M Y Y Y 1 N Y N Y Y N
49 NAGAPPAN5997/13 47 M Y Y Y 4 N Y Y Y Y N
50 BALACHANDER5982/13 34 M Y Y N N N Y N Y Y N
51 PITCHANDI 6093/13 45 M Y Y N N N N N Y N HBV
52 SARBUDEEN4341/11 49 M Y Y Y 3 N Y N N N HCV
53 ARIF KHAN 3487/12 54 M Y Y Y 4 N Y Y N N NAFLD
54 SURESH 3258/13 30 M Y Y N N Y N N N Y N
55 ELANGO 1245/13 43 M Y Y N N N N N Y Y N
56 RAJI 324/10 43 F Y Y N N N Y N N N HBV
57 KARTHIBAN2367/11 64 M Y Y N N N Y N N Y N
58 SURESH 3254/11 54 M Y Y N N N Y N N Y N
59 MALAIVASAN4356/12 45 M Y Y N N N Y N N Y N
60 ANGAMUTHU3456/10 47 M Y Y Y 3 N Y N N Y N
61 RAVI.G 6543/11 43 M Y Y N N N Y N N Y HBV
62 GUNAVATHI6688/13 45 F Y Y Y 3 N Y Y N N NAFLD
63 RANI 6548/10 56 F Y Y Y 3 N Y N N N HCV
64 SARITHA 4325/11 43 F Y Y Y 3 N Y N N N HBV
65 VENKATESAN4765/12 54 M Y N N N N N N Y Y N
66 KARUNANIDHI6543/10 65 M Y Y N N N N N N Y N
67 VARATHARAJAN109/14 56 M Y Y N N N N N N N NAFLD
68 KUMARAN 156/14 45 M Y N N N N N N Y Y N
69 RAVIKUMAR1234/14 46 M Y Y Y 1 N Y N N Y N
70 ELDER BONES213/14 50 M Y Y Y 4 N Y N Y Y N
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N N Y 8100 8.3 1.81 145 20 0.7 137 3.2 16.9 356 231
N N Y 11,000 10.6 1.7 156 21 0.8 137 3.2 13 6.2 384
N N Y 5500 6.5 0.7 134 22 0.7 134 3.2 11 386 286
Y Y Y 4900 8.3 2.5 148 21 0.8 136 3.6 6.5 354 275
Y N N 4400 7.1 0.7 135 22 0.9 136 3.8 4.1 124 134
N N Y 4400 8.8 0.65 143 45 2 122 2.4 13 454 420
N N Y 6000 6 0.7 135 37 1.7 122 2.6 14 565 467
N N Y 5800 8 0.75 129 22 2.3 134 3.6 12 254 235
N N Y 5600 8 0.8 125 24 0.9 134 3.5 13 345 324
N N Y 4500 8.9 0.7 127 30 3.5 141 4.1 14 280 260
N N Y 8000 9 1.2 137 34 3.2 141 3.3 3 128 126
Y N N 6000 9 1.1 245 22 3.5 136 4.2 8 458 468
N N Y 7800 6 0.5 145 34 1.7 122 2.5 6 565 543
N N Y 7000 9.8 1.2 124 22 0.7 134 3.7 6 256 234
N N Y 4900 9.9 0.6 110 38 0.9 141 3.1 6.4 342 245
N N N 6700 9 0.7 145 23 0.8 141 4.5 6 245 234
N N Y 6000 7 0.8 176 23 0.9 143 3.6 7 234 254
N N Y 5600 7 0.6 134 23 0.8 137 3.7 7 457 453
N N N 6000 8 0.8 134 21 0.9 138 3.5 5 234 123
Y Y Y 7000 10 1.2 134 23 0.9 137 3.4 6 126 135
N N Y 8000 9 1.2 156 23 0.9 145 3.6 5 345 234
N N Y 5600 6 0.8 134 23 0.7 136 3.7 5 245 234
Y N Y 7800 8 1.1 124 24 0.7 138 3.2 7 256 234
Y Y Y 6700 5 0.5 122 23 1.5 123 2.4 2 654 543
Y Y Y 4500 8 1.1 145 25 0.7 143 3.8 7 236 231
Y Y Y 5600 6 1.2 134 23 3.5 138 2.6 7 134 121
N N N 7890 11 0.9 145 34 3.5 145 4.2 6 345 321
N N N 8600 8 0.6 143 34 0.9 142 4.5 7 254 231
N N Y 5670 9.6 0.8 123 27 0.7 139 3.8 7 239 123
Y Y Y 4500 6 0.5 145 50 1.5 132 2.5 21 874 834
N N Y 5600 12 0.7 143 32 1.1 129 2.7 21 432 324
N N N 5400 8 1.2 145 28 0.9 134 2.7 7 342 236
N N N 7600 6 0.45 123 34 0.8 135 3.5 7 125 121
Y Y Y 6700 8 0.7 145 35 0.8 134 3.2 7 235 214
N N Y 6500 9.6 0.67 157 25 0.8 143 3.6 8 345 234
N Y Y 7800 8 1.1 145 34 0.8 145 3.7 7 234 212
N N N 11000 5 0.56 123 34 1.7 143 3.7 7 267 245
N N Y 13000 7 0.67 111 45 2.7 111 4.5 21 876 834
N N Y 7800 6 0.54 121 56 4.3 114 5.7 16 654 542
N N N 4500 12 0.78 134 22 0.7 36 4.5 5 223 212
N N Y 6700 9.7 1.4 123 23 0.8 138 4.2 6 432 345
N N N 4500 10.7 0.78 154 26 0.8 142 4.5 8 342 324
Y Y Y 7800 5 0.67 165 45 2.1 111 4.3 23 765 769
N N Y 5400 6 1.3 213 34 3.3 114 5.5 26 654 765
N N N 4500 13 1.5 123 23 0.6 143 4.3 4 234 224
N N N 9000 2 1.8 134 24 0.8 143 3.9 2 76 67
N N Y 5600 8 1.2 137 27 0.5 145 4.7 7 321 253
N N N 5700 8.6 0.76 148 25 0.6 142 4.1 5 435 345
Y Y Y 4300 8 0.45 111 25 0.8 142 4.6 14 234 213
N N Y 5200 13 0.75 125 26 0.7 137 3.7 18 432 378
N N N 7600 7 0.85 132 24 0.6 136 3.5 19 225 214
N N Y 5400 8.4 0.54 143 28 0.7 141 4.2 23 984 876
N N N 6500 7 0.45 123 34 3.2 123 2.4 25 784 654
N N Y 4500 8 0.67 134 23 0.6 145 3.7 15 342 256
N N N 7800 12 1.3 126 21 0.9 143 3.4 14 231 23
N N N 4300 7.4 0.45 132 21 0.6 142 3.6 21 211 207
N N Y 6700 12 0.8 154 28 0.9 143 4.2 24 894 765
N N Y 5400 8 0.67 134 34 4.2 145 4.3 21 674 543
N N Y 5500 9 0.56 123 34 1.7 139 4.4 17 453 432
N N Y 4500 7 0.67 154 23 0.7 143 4.5 17 345 321
N N Y 5600 9 0.87 143 23 0.8 138 3.2 21 567 543
N N N 7600 8 0.75 134 23 0.8 139 3.5 16 453 345
N N N 4700 8 0.65 145 23 0.8 137 3.6 18 348 212
N N N 7600 12 0.87 154 27 0.9 138 3.6 17 342 321
N N N 7600 14 1.6 154 32 0.9 145 4.6 2 43 34
N N N 7800 8 0.9 143 23 0.9 139 4.7 3 65 54
N N N 6700 8 0.76 143 23 0.7 136 4.2 17 109 111
N N N 8700 9 0.67 143 23 0.9 143 3.8 4 78 56
N N N 4500 8 0.56 156 24 0.7 143 4.2 13 109 123
N N Y 4500 6 0.78 165 34 2.3 32 2.6 21 456 654
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232 6.9 3.5 22.6 1.66 Y Y N N N N Y N N
364 129 6.1 20.6 1.45 Y Y N N N N Y N N
210 5.8 2.8 22 1.6 Y Y N N N N N N N
224 5.8 2.4 24 1.8 Y Y N N N N Y N N
100 5.7 2.2 21 1.5 N N N N N N Y N N
124 5.6 2.2 35 2.5 Y Y Y N N N Y N N
123 5.3 2.1 21 1.5 Y Y N N N N Y N N
108 5.9 2.4 21 1.4 Y Y N N N N Y N N
108 5.6 2.2 20 1.4 Y Y N N N N Y N N
89 5.4 2.2 13 1.01 Y Y N N N N Y N N
67 6.2 3 14 1.02 Y Y N N N Y N N Y
209 6.2 3.2 31 2.48 Y Y N N N N N N N
210 5.3 2.1 32 1.7 Y Y N N N N Y N N
98 5.9 2.9 19 1.5 Y Y N N N N Y N N
112 5.6 2.2 28 3.17 Y Y N N N N Y N N
89 6 3.4 24 1.5 Y N N N N N Y N N
123 5 2.7 26 1.7 Y Y N N N N Y N N
123 6.1 3.4 25 1.9 Y Y N N N N Y N N
78 6.3 3.7 14 1.01 N N N N N Y N N Y
90 6 3 13 1.01 Y Y N N N Y N N Y
123 5.2 2.3 21 1.7 Y Y N N N N Y N N
122 5.7 2.5 21 1.6 Y Y N N N N Y N N
109 6 2.4 21 1.8 Y Y N N N N Y N N
103 5.4 2.2 25 1.7 Y Y N N N N Y N N
108 5.8 2.4 21 1.6 Y Y Y N N N Y N N
78 6 2.4 19 1.56 Y Y N N N N N N N
99 6 3.6 13 1.03 N N N N N N N Y N
108 5.2 2.5 24 1.89 Y Y N N N N N N N
78 5.4 2.4 24 1.56 Y Y N N N N Y N N
154 5 2.1 26 2.56 Y Y Y N N N N N N
122 5 2.5 23 1.5 Y Y N N N N Y N N
111 6.4 3.6 13 1.01 Y Y N N N Y N N Y
89 5.4 2.7 23 1.87 Y Y N N N N Y N N
90 5.7 2.4 21 1.9 Y Y Y N N N Y N N
102 6 2.9 21 1.9 Y Y N N N N Y N N
109 7 3.2 25 2.78 Y Y N N N N N N N
101 5.4 2.2 27 2.67 Y Y N N N N N N N
107 5.2 2.2 28 2.89 Y Y Y N N N Y N N
112 5.3 2.1 32 2.89 Y Y N N N N Y N N
108 5.6 2.5 21 1.76 Y Y N N N N N N N
87 5.7 2.6 21 1.87 Y N N N N N Y N N
111 6 3.2 27 2.4 Y Y N N N N Y N N
112 5.3 2.1 34 3.14 Y Y N N N N Y N N
134 5.3 2.5 32 2.9 Y Y Y N N N Y N N
87 6 2.9 14 1.04 Y N N N N N N N Y
98 6.7 3.7 13 1.01 N N N N N N N Y N
117 5.6 2.4 28 2.79 Y Y N N N N Y N N
102 5.2 2.3 25 1.4 Y Y N N N N Y N N
101 5.3 2.1 25 1.67 Y Y N N N N Y N N
88 5.1 2.3 29 1.9 Y Y N N N N Y N N
101 5.4 2.4 26 1.72 Y Y N N N N N N N
106 5.1 2.1 34 2.89 Y Y N N N N N N N
112 56 2.2 34 2.9 Y Y N N N N N N N
101 5.6 2.5 23 1.78 Y Y N N N N Y N N
89 5.9 2.3 23 1.8 Y Y N N N N Y N N
76 5.3 2.1 24 2.1 Y Y N N N N N N N
123 5.6 2.1 25 2.6 Y Y N N N N Y N N
111 5.9 2.7 25 2.1 Y Y N N N N Y N N
111 5.6 2.5 23 1.7 Y Y N N N N Y N N
234 5.9 3 25 2.1 Y Y N N N N Y N N
123 6 3.2 21 1.67 Y Y N N N N Y N N
102 5.8 2.6 18 1.5 Y N N N N N N N N
200 5.9 3.2 21 1.6 Y N N N N N N N N
127 6 3.4 26 1.9 Y Y N N N N N N N
109 6.4 3.6 13 1 N N N N N N N Y N
78 6.4 3.8 13 1.01 N N N N N Y N Y N
98 6.2 4 15 1.1 Y N N N N N N N Y
89 6 3.5 13 0.9 N N N N N Y N Y N
145 6 3 17 1.5 Y N N N N Y N N
145 5.3 2.1 27 1.6 Y Y N N N N Y N N
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Y N N Y 24.6 N N Y D Y N MOF 629
Y N N Y 28.6 N N Y D Y N MOF 567.6
Y N N Y 22.8 N N Y D Y N MOF 941
Y N N Y 21.4 N N Y D Y N MOF 662.2
Y N N Y 26.5 Y N N A N Y 106
Y N N Y 25 N N Y D Y N MOF 447.7
Y N N Y 28 N N Y D Y N MOF 2045
Y N N Y 23.6 N N Y D Y N MOF 736.9
Y N N Y 22.5 N N Y D Y N MOF 1034
Y N N Y 23.4 N Y N A N Y 356
N N Y N 15.6 Y N N A N Y 36
Y N N Y 24.8 N N Y D Y N MOF 1471
Y N N Y 34 N N Y D Y N MOF 957
Y N N Y 27.5 Y N N A N Y 112
Y N N Y 25.4 N N Y D Y N MOF 967
Y N N Y 23.2 Y N N A N Y 133
Y N N Y 29.8 Y N N A N Y 36.8
Y N N Y 24.2 Y N N A N Y 67
N Y N N 7.6 Y N N A N Y 107
N Y N N 8.4 Y N N A N Y 145
Y N N Y 24 N Y N A N Y 312
Y N N Y 27.5 N N Y D Y N MOF 668
Y N N Y 26.4 Y N N A N Y 33.9
Y N N Y 34.7 N N Y D Y N MOF 1229.8
Y N N Y 35.6 Y N N D Y N MOF 137
Y N N Y 27.5 N N Y D Y N MOF 774
N Y N N 8.4 Y N N A N Y 143
Y N N Y 29.4 N N Y D Y N MOF 1654
Y N N Y 29.8 N N Y D Y N MOF 986
Y N N Y 23.7 N N Y D Y N MOF 876
Y N N Y 22.4 N N Y A N Y 321
N N Y N 16.5 N N Y A N Y 765
Y N N Y 24.7 N N Y A N Y 654
Y N N Y 23.4 N N Y D Y N MOF 1098
Y N N Y 32.4 N N Y D Y N MOF 2134
Y N N Y 26 Y N N A N Y 67
Y N N Y 31.3 N N Y D Y N MOF 1876
Y N N Y 26.3 N N Y D Y N MOF 1654
Y N N Y 32.6 N N Y D Y N MOF 976
Y N N Y 27.4 N Y N D N Y 245
Y N N Y 28.5 N N Y D Y N MOF 879
Y N N Y 25.3 N N Y A N Y 783
Y N N Y 24 N N Y D Y N MOF 2063
Y N N Y 26 N N Y D Y N MOF 1256
N N Y N 18.4 N Y N A N Y 321
N Y N N 6.4 Y N N A N Y 56
Y N N Y 23.5 N Y N D Y N MOF 234
Y N N Y 26 N Y N A N Y 45
Y N N Y 21 N N Y D Y N MOF 764
Y N N Y 32.6 N Y N A Y N MOF 313
Y N N Y 28.7 N Y N A N Y 276
Y N N Y 24.7 N N Y A Y N MOF 843
Y N N Y 27 N N Y D Y N MOF 1876
Y N Y N 15.7 N Y N A N Y 369
Y N Y N 17.4 Y N N A N Y 54
Y N N Y 28 N Y N A N Y 389
Y N N Y 24.5 N Y N A N Y 264
Y N N Y 36.7 N N Y A N Y 2063.3
Y N N Y 34.6 Y N N A N Y 8.8
Y N N Y 28.5 N Y N A N Y 290
Y N N Y 25.6 N N Y A N Y 1160
Y N Y N 12.8 N Y N A N Y 265
Y N N Y 29.6 Y N N A N Y 132
Y N N Y 27.8 N Y N A N Y 276
N Y N N 7.4 Y N N A N Y 45
N Y N N 7.8 N N Y A N Y 2654
N N Y N 17 N Y N A N Y 102
N Y N N 7.4 N Y N A N Y 377
Y N Y N 16.9 N Y N A N Y 245
Y N N Y 28 N N Y D Y N MOF 1524
608.0281
KEYS TO MASTER CHART
M MALE
F FEMALE
Y YES
N NO
A ALIVE
D DEAD
MOF MULTI-ORGAN FAILURE
HBV HEPATITIS B VIRUS
HCV HEPATITIS C VIRUS
NAFLD NON-ALCOHOLIC FATTY LIVER DISEASE
